Invasive pneumococcal disease among children with and without sickle cell disease in the United States, 1998 to 2009

Pediatric Infectious Disease Journal

Volumn 32, Issue 12, 2013, Pages 1308-1312

  Payne, Amanda B ^a   Link Gelles, Ruth ^b   Azonobi, Ijeoma ^a   Hooper, W Craig ^a   Beall, Bernard W ^b   Jorgensen, James H ^c   Juni, Billie ^d   Moore, Matthew ^b  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d MINNESOTA DEPARTMENT OF HEALTH   (United States)

Author keywords

Pneumococcal conjugate vaccine; Sickle cell disease; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE;

ADOLESCENT; AFRICAN AMERICAN; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NEWBORN SCREENING; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SEROTYPE; SICKLE CELL ANEMIA; TREND STUDY; UNITED STATES; ANEMIA, SICKLE CELL; BLOOD; INCIDENCE; INFANT; MICROBIOLOGY; NEWBORN; PNEUMOCOCCAL INFECTIONS; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADOLESCENT; AFRICAN AMERICANS; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84891742904     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182a11808     Document Type: Article

References (32)

1. Ramakrishnan M, Moïsi JC, Klugman K P, et al. Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:329-337.
2. Poehling KA, Light LS, Rhodes M, et al. Sickle cell trait, hemoglobin C trait, and invasive pneumococcal disease. Epidemiology. 2010;21: 340-346.
3. Pearson HA. Sickle cell anemia and severe infections due to encapsulated bacteria. J Infect Dis. 1977;136(suppl):S25-S30.
4. Adamkiewicz T V, Sarnaik S, Buchanan GR, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr. 2003;143:438-444.
5. Centers for disease control and prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46:1-24.
6. O'Brien KL, Swift AJ, Winkelstein JA, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics. 2000;106:965-972.
7. Centers for disease control and prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2000;49:1-35.
8. Yanni E, Grosse SD, Yang Q, et al. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. Journal Pediatr. 2009;154:541-545.
9. Davies EG, Riddington C, Lottenberg R, et al. Pneumococcal vaccines for sickle cell disease. Cochrane Database Syst Rev. 2004:CD003885.
10. Pilishvili T, Lexau C, Farley MM, et al.; Active bacterial core surveillance/emerging infections program network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
11. Mccavit TL, Xuan L, Zhang S, et al. Hospitalization for invasive pneu-mococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure. Pediatr Blood Cancer. 2012;58:945-949.
12. Mccavit TL, Quinn CT, Techasaensiri C, et al. Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure. J Pediatr. 2011;158:505-507.
13. Moore MR, Gertz RE Jr, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197:1016-1027.
14. Beall B W, Gertz RE, Hulkower RL, et al. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis. 2011;203:1360-1368.
15. Schuchat A, Hilger T, Zell E, et al.; Active bacterial core surveillance team of the emerging infections program network. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis. 2001;7:92-99.
16. Centers for disease control and prevention. Active Bacterial Core surveillance (ABCs) March 25, 2011. Available at: http://www.cdc.gov/abcs/ reports-fndings/survreports/spneu10.html. Accessed November 28, 2012.
17. Clinical and laboratory standards institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-second Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
18. Park IH, Moore MR, Treanor JJ, et al.; Active bacterial core surveillance team. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis. 2008;198:1818-1822.
19. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(suppl 4):S512-S521.
20. United States department of health and human services centers for disease control and prevention, national center for health statistics (NCHS), division of vital statistics. CDC WONDER Natality Information-Live Births, on CDC WONDER online database. Available at: http://wonder.cdc.gov/natal-ity.html. Accessed December 1, 2012.
21. Therrell BL, Hannon WH. National evaluation of US newborn screening system components. Ment Retard Dev Disabil Res Rev. 2006;12:236-245.
22. Quinn CT, Rogers ZR, Mccavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115:3447-3452.
23. United States department of health and human services centers for disease control and prevention, national center for health statistics (NCHS), Division of vital statistics. Bridged-Race Population Estimates, United States July 1st resident population by state, county, age, sex, bridged-race, and Hispanic origin, compiled from 1990-1999 bridged-race intercensal population estimates and 2000-2008 (Vintage 2008) bridged-race postcensal population estimates, on CDC WONDER online database. Available at: http://wonder.cdc.gov/bridged-race- population.html. Accessed December 1, 2012.
24. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196:1346-1354.
25. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumo-coccal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44:1428-1433
26. Battersby AJ, Knox-Macaulay HH, Carrol ED. Susceptibility to invasive bacterial infections in children with sickle cell disease. Pediatr Blood Cancer. 2010;55:401-406.
27. Section on hematology/oncology committee on g, American academy of p. Health supervision for children with sickle cell disease. Pediatrics. 2002;109:526-535
28. American academy of pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumo-coccal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362-366.
29. Centers for disease control and prevention. Use of 13-valent pneumococ-cal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR. 2013;62:521-524.
30. Cooper D, Yu X, Sidhu M, et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011;29:7207-7211.
31. Herz AM, Greenhow TL, Alcantara J, et al. Changing epidemiology of outpatient bacteremia in 3-to 36-month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine. Pediatr Infect Dis J. 2006;25:293-300
32. National heart l, and blood institute, division of blood diseases and resources. The Management of Sickle Cell Disease. 4th ed. Bethesda, MD: National Institutes of Health; 2002.